UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia

The New England journal of medicine, 2013-07, Vol.369 (3), p.224-232

2013

Volltextzugriff (PDF)

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry

Diabetes care, 2015-06, Vol.38 (6), p.971-978

2015

Volltextzugriff (PDF)

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

Diabetes care, 2016-11, Vol.39 (11), p.1972-1980

2016

Volltextzugriff (PDF)

Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group

Diabetologia, 2020-02, Vol.63 (2), p.229-241

2020

Volltextzugriff (PDF)

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

Diabetes care, 2017-07, Vol.40 (7), p.943-950

2017

Volltextzugriff (PDF)

Update on Measuring Ketones

Journal of Diabetes Science and Technology, 2024-05, Vol.18 (3), p.714-726

2024

Volltextzugriff (PDF)

Continuous glucose monitoring: transforming diabetes management step by step

The Lancet (British edition), 2018-04, Vol.391 (10128), p.1334-1336

Bergenstal, Richard M

2018

Volltextzugriff (PDF)

Advances in technology for management of type 1 diabetes

The Lancet (British edition), 2019-10, Vol.394 (10205), p.1265-1273

2019

Volltextzugriff (PDF)

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Diabetologia, 2015-03, Vol.58 (3), p.429-442

2015

Volltextzugriff (PDF)

Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group

Diabetes care, 2020-01, Vol.43 (1), p.250-260

2020

Volltextzugriff (PDF)

A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial

The Lancet (British edition), 2021-01, Vol.397 (10270), p.208-219

2021

Volltextzugriff (PDF)

Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections

Diabetes care, 2017-04, Vol.40 (4), p.554-560

2017

Volltextzugriff (PDF)

Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2021-06, Vol.325 (22), p.2262

2021

Volltextzugriff (PDF)

Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA)

Diabetologia, 2020-12, Vol.63 (12), p.2501-2520

2020

Volltextzugriff (PDF)

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

Diabetes care, 2015-12, Vol.38 (12), p.2217-2225

2015

Volltextzugriff (PDF)

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

Diabetes care, 2021-07, Vol.44 (7), p.1586-1594

2021

Volltextzugriff (PDF)

728-P: Glycemic Variability of Tirzepatide vs. Insulin Degludec in People with Type 2 Diabetes Using Continuous Glucose Monitoring (SURPASS-3 CGM)

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

Randomized comparison of self-monitored blood glucose (BGM) versus continuous glucose monitoring (CGM) data to optimize glucose control in type 2 diabetes

Journal of diabetes and its complications, 2022-03, Vol.36 (3), p.108106-108106, Article 108106

2022

Volltextzugriff (PDF)

717-P: Real-World, Patient-Reported Data on Training and Use of 670G Hybrid Closed-Loop (HCL) among Children and Adults with Type 1 Diabetes (T1D)

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association

Diabetologia, 2023-01, Vol.66 (1), p.3-22

2023

Volltextzugriff (PDF)

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial

Annals of internal medicine, 2011-01, Vol.154 (2), p.103

2011

Volltextzugriff (PDF)

Response to Comment on Aleppo et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care 2021;44:2729-2737

Diabetes care, 2022-04, Vol.45 (4), p.e85-e86

2022

Volltextzugriff (PDF)

Improving the clinical value and utility of CGM systems: issues and recommendations: A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group

Diabetologia, 2017-12, Vol.60 (12), p.2319-2328

2017

Volltextzugriff (PDF)

The Association of Biochemical Hypoglycemia with the Subsequent Risk of a Severe Hypoglycemic Event: Analysis of the DCCT Data Set

Diabetes technology & therapeutics, 2019-01, Vol.21 (1), p.1-5

2019

Volltextzugriff (PDF)

A Roadmap to an Equitable Digital Diabetes Ecosystem

Endocrine practice, 2023-03, Vol.29 (3), p.179-184

2023

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Aktive Filter

ThemaInsulin

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(86)

Publikationsform

Artikel
(103)

Sprache

Englisch
(103)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Diabetes
(95)
Life Sciences & Biomedicine
(69)
Science & Technology
(69)
Humans
(63)
Endocrinology & Metabolism
(57)
Glucose
(52)
Hypoglycemia
(51)
Diabetes Mellitus
(50)
Glucose Monitoring
(40)
Female
(35)
Male
(35)
Adult
(31)
Blood Glucose
(29)
Hypoglycemic Agents - Therapeutic Use
(28)
Diabetes Mellitus, Type 1 - Drug Therapy
(27)
Insulin - Therapeutic Use
(26)
Middle Aged
(26)
Blood Glucose Self-Monitoring
(23)
Diabetes Mellitus, Type 2 - Drug Therapy
(23)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

Update on Measuring Ketones

Continuous glucose monitoring: transforming diabetes management step by step

Advances in technology for management of type 1 diabetes

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group

A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial

Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections

Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

728-P: Glycemic Variability of Tirzepatide vs. Insulin Degludec in People with Type 2 Diabetes Using Continuous Glucose Monitoring (SURPASS-3 CGM)

Randomized comparison of self-monitored blood glucose (BGM) versus continuous glucose monitoring (CGM) data to optimize glucose control in type 2 diabetes

717-P: Real-World, Patient-Reported Data on Training and Use of 670G Hybrid Closed-Loop (HCL) among Children and Adults with Type 1 Diabetes (T1D)

Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial

Response to Comment on Aleppo et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care 2021;44:2729-2737

Improving the clinical value and utility of CGM systems: issues and recommendations: A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group

The Association of Biochemical Hypoglycemia with the Subsequent Risk of a Severe Hypoglycemic Event: Analysis of the DCCT Data Set

A Roadmap to an Equitable Digital Diabetes Ecosystem

Aktive Filter

Suchergebnisse filtern